Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has completed and commissioned a new high containment facility for potent product manufacture at its Edinburgh, UK site, Macfarlan Smith.

Macfarlan Smith is a provider of opiates, controlled substance and highly potent products; the new self-contained, state-of-the-art facility is required to meet existing demand for potent products and also provides additional capacity for anticipated future requirements. It features isolators containing a range of hastelloy and glass vessels, with powder transfers being mediate through split butterfly values with active valve wash stations. It also contains a dedicated finishing room, QC laboratory and control room.

“This new facility is a significant addition to our existing capabilities at our site in Edinburgh,” said Steve Barr, vice president business development Europe. “It enhances our overall capabilities in high containment manufacturing and provides extra capacity to extend our range of high potency products and services. These facilities support Johnson Matthey’s broader assets for the manufacture of highly potent products including our U.S. capacity in West Deptford, NJ and Devens, MA.”